NOVADISCOVERY presents first results from the in silico component of the exploratory clinical program initiated by ENYO Pharma on EYP001, a non-bile acid FXR receptor agonist currently in phase 1b trial for the treatment of chronic Hepatitis B.
to accelerate the clinical development of drug candidate EYP001.
October 2, 2017
In the presence of Mme Françoise Grossetête, Member of the European Parliament & Dr Adriano Henney, Secretary General of Avicenna Alliance.
The Avicenna Alliance has claimed a major victory in the revised EMA Regulation with the introduction of new text supporting modeling and simulation and predictive medicine in medicinal product development
The Avicenna Alliance, which Nova is a founding member of, releases its roadmap “in silico Clinical Trials: How Computer Simulation will Transform the Biomedical Industry”. This roadmap has been approved by the European Commission.